Low-dose Aspirin may Prevent Preeclampsia by Inhibiting the Expression
of ATF2
-
Published:2023-04
Issue:5
Volume:23
Page:702-710
-
ISSN:1871-5303
-
Container-title:Endocrine, Metabolic & Immune Disorders - Drug Targets
-
language:en
-
Short-container-title:EMIDDT
Author:
Liu Rong1,
Xiao Sha1,
Guo Lu1,
Zhang Ming1,
Hu Rong1
Affiliation:
1. Department of Obstetrics and Gynecology, Tianjin First Center Hospital, Tianjin 300192, China
Abstract
aims:
To explore the ATF2 expression of preeclampsia patients and investigate whether the level of ATF2 expression impacted the low-dose aspirin treatment of preeclampsia patients.
background:
Preeclampsia is a severe pregnancy-related hypertension disorder and refers to hypertension.
objective:
To explore the ATF2 expression of preeclampsia patients and investigate whether the level of ATF2 expression impacted the low-dose aspirin treatment of preeclampsia patients.
method:
Firstly, we collected the plasma of normal and preeclampsia pregnancies and quantified the expressions of ATF2 by ELISA. Then we quantified the expression of the three downstream target genes of ATF2 (IL-8, IL-6 and MMP-2). Finally, we collected and quantified the interventional and observational group plasma, which were different from LDA administration. All data were compared by t-test (P<0.05).
result:
ATF2 and its target genes (IL-6, IL-8 and MMP-2) were upregulated in preeclampsia patients. In addition, ATF2 and its target genes were downregulated in the interventional group.
conclusion:
Our results indicated that LDA could inhibit ATF2 expression in preeclampsia. It suggests that ATF2 may be a potential target of LDA in the prevention of preeclampsia.
other:
None.
Publisher
Bentham Science Publishers Ltd.
Subject
Immunology and Allergy,Endocrinology, Diabetes and Metabolism